Implied tracks the companies making the biggest moves — because when a stock swings hard, something big might be changing. Each 3-minute episode breaks down what just happened and why it matters, digging into earnings, filings, and market reactions to uncover what could come next.
AST SpaceMobile Plunges 11.6% After SpaceX Swoops In — Has Elon Musk Stolen the Space Race?
AST SpaceMobile just took a massive hit, dropping 11.6% after Elon Musk’s SpaceX reportedly snatched up the highly coveted 800 MHz spectrum block it desperately needed. With a painful $230 million net loss, recent share dilution, and heavy insider selling, Wall Street is hitting the panic button on the direct-to-cell startup. But with a $2.7 billion war chest, 13 satellites already in orbit, and a $1.3 billion revenue backlog, AST isn't running on fumes just yet. In this episode of Implied, we break down what this fierce rivalry means for the telecom world and whether this massive selloff is a red flag… or a rare buy-the-dip opportunity for long-term value hunters.
23 Sept 2026
Planet Fitness Has Plunged 50% — Value Trap or Massive Buy-the-Dip Opportunity?
Planet Fitness has taken a heavy beating over the last year, plummeting over 50% from its 52-week high of $114 down to the low-$50s. But beneath the Wall Street noise, the underlying data reveals a classic value setup. Despite macro headwinds, the gym giant just beat Q2 earnings, proved strong pricing power after raising member fees by 50%, and sparked a massive insider buying spree from the CEO and board members. In this episode of Implied, we break down whether Wall Street has severely mispriced $PLNT's resilient franchise model—or if tightening consumer budgets pose a real threat. Tune in to see if this steep selloff signals danger or a rare chance to buy high-margin growth on sale.
22 Sept 2026
Novo Nordisk Plunges 8% After Weak 2030 Outlook — Wall Street Overreaction or Patent Cliff Panic?
Novo Nordisk shares just plummeted 8% after management’s Capital Markets Day left Wall Street underwhelmed by its growth targets through 2030. Despite trading at a bargain P/E of 9.7 with a solid 4% dividend yield, investors panicked over the upcoming 2032 Wegovy and Ozempic patent cliff, slowing prescription growth, and mounting competition from Eli Lilly. In this episode of Implied, we break down whether this steep selloff is an emotional Wall Street overreaction that creates a classic value entry point—or a warning that the pharma giant’s explosive growth era is coming to an end. Tune in for the full story behind the drop!
Reach and audience
Public platform figures. Ratings count people who left a rating, not total listeners.
Spotify
5.0 / 5
1 ratings
Contact Implied Podcast
Guest appearances
Does not typically book guests
Based on episode analysis; this does not confirm that the show is currently accepting guests.
Host of Implied Podcast?
Claim your podcast to manage its listing and keep your show details accurate.
Pod Engine is an independent podcast discovery and analytics service and is not affiliated with or endorsed by this podcast. Artwork and show content belong to their owners. Full legal notice.
Explore this show Podcast research with Pod Engine
